Tower Research Capital (TRC)’s Genetic Technologies Ltd. GENE Stock Holding History

Tower Research Capital (TRC)’s Portfolio GENE Stock Details GENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-18	Closed	-$13	–	6191
2024 Q3	$13	Buy	+18	New	+$16	﹤0.01%	5620
2023 Q2	–	Sell	-1	Closed	–	–	6462
2023 Q1	$0	Buy	+1	New	+$6	﹤0.01%	6474
2016 Q1	–	Sell	-17	Closed	-$1K	–	5119
2015 Q4	$1K	Sell	17 -151	-90%	-$7.62K	﹤0.01%	4198
2015 Q3	$6K	Sell	168 -873	-84%	-$46.8K	﹤0.01%	2704
2015 Q2	$63K	Buy	+1,041	New	+$87.2K	0.01%	1188
2014 Q3	–	Sell	-42	Closed	-$4K	–	4988
2014 Q2	$4K	Sell	42 -86	-67%	-$10.3K	﹤0.01%	3049
2014 Q1	$18K	Buy	128 +112	+700%	+$17.9K	﹤0.01%	2019
2013 Q4	$2K	Buy	16 +1	+7%	+$186	﹤0.01%	4069
2013 Q3	$3K	Buy	15 +10	+200%	+$2.38K	﹤0.01%	3986
2013 Q2	$1K	Buy	+5	New	+$1.3K	﹤0.01%	3757

Other funds holding GENE

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Tower Research Capital (TRC)'s GENE Position: Q4 2024 in Review

Tower Research Capital (TRC) sold out of Genetic Technologies Ltd. (GENE) in Q4 2024, closing a stake of 18 shares — an estimated $13 sold.

Tower Research Capital (TRC) first reported a position in GENE in Q2 2013 and held it in 10 quarters. The position peaked at $63K in Q2 2015. 1 fund tracked by Wall St. Rank holds GENE as of Q4 2024.

Tower Research Capital (TRC) reported no remaining Genetic Technologies Ltd. position as of Q4 2024 after selling out during the quarter.
Tower Research Capital (TRC) sold 18 Genetic Technologies Ltd. shares in Q4 2024, an estimated $13.
Tower Research Capital (TRC) first reported a position in Genetic Technologies Ltd. in Q2 2013 and held it in 10 quarters.
Tower Research Capital (TRC)'s Genetic Technologies Ltd. position peaked at $63K in Q2 2015.
1 fund tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q4 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2024, filed 13 Feb 2025.